Illumina (NASDAQ:ILMN) Releases FY25 Earnings Guidance

Illumina (NASDAQ:ILMN) updated its FY25 earnings guidance on Monday. The company provided earnings per share (EPS) guidance of $4.50 for the period, compared to the consensus estimate of $4.51. Illumina also updated its FY 2025 guidance to 4.500-4.500 EPS.

Illumina Stock Performance

NASDAQ ILMN opened at $84.52 on Wednesday. The firm’s 50 day simple moving average is $116.45 and its 200 day simple moving average is $130.84. Illumina has a 1 year low of $80.18 and a 1 year high of $156.66. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $13.39 billion, a price-to-earnings ratio of -11.01, a P/E/G ratio of 1.60 and a beta of 1.17.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, research analysts expect that Illumina will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the topic of several recent research reports. Morgan Stanley cut their target price on Illumina from $150.00 to $136.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 11th. TD Cowen lowered shares of Illumina from a “buy” rating to a “hold” rating and dropped their target price for the company from $177.00 to $140.00 in a report on Friday, February 7th. Barclays downgraded Illumina from an “equal weight” rating to an “underweight” rating and dropped their price objective for the company from $130.00 to $100.00 in a research note on Monday, February 10th. Canaccord Genuity Group dropped their price target on Illumina from $135.00 to $115.00 and set a “hold” rating on the stock in a research note on Tuesday. Finally, Hsbc Global Res lowered Illumina from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $146.85.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.